Compare stocks

PBH vs RVMD

Prestige Consumer Healthcare Inc. and Revolution Medicines, Inc. Common Stock

Compare the businesses

Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under Debrox brand name. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Open PBH dashboard ↗

Revolution Medicines, Inc. Common Stock

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Open RVMD dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

Sign in →

New to NexusTrade? Create a free account.

Choose another comparison ↗